Copyright
©The Author(s) 2020.
World J Clin Oncol. Feb 24, 2020; 11(2): 74-82
Published online Feb 24, 2020. doi: 10.5306/wjco.v11.i2.74
Published online Feb 24, 2020. doi: 10.5306/wjco.v11.i2.74
Ref. | Topic | Patients | (Prevalent) Histological subtype(s) | Chemotherapy/ radiotherapy | Outcome (after diagnosis of metastasis) | |
Total number of STS (n), of whom eSTS, n (%) | Of whom eSTS with AM/RM, n (%) | |||||
Thompson et al[16], 2015 | Diagnostic pathway | 140 (100) | 7 (5.0) AM | Epithelioid sarcoma, leiomyosarcoma, liposarcoma, synovial sarcoma | N/A | N/A |
King et al[9], 2009 | Diagnostic pathway, outcome | 124 (100) | 7 (5.6) AM | MPNST, leiomyosarcoma, myxofibrosarcoma, pleomorphic sarcoma | N/A | 21% mortality rate (n = 21/124) |
Gorelik et al[6], 2018 | Diagnostic pathway | 33 (100) | 4 (12.1) AM | Myxoid liposarcoma | 89% of patients with metastases (including others than AM) received neoadj. RTX 22% received adj. RTX for primary tumour | N/A |
Behranwala et al[8], 2004 | Therapeutic approach | 2127 (100) | 19 (0.9) AM | Myxoid liposarcoma, leiomyosarcoma | CTX + RTX in 3 patients, and CTX or RTX in 1 patient each following resection of AM | Median OS: 12 mo |
Ogose et al[11], 2000 | Therapeutic approach | 282 (100) | 24 (8.5) AM | Liposarcoma | None of patients with AM received RTX or CTX | Mean OS (liver/GI metastases): 4.6 mo; Mean OS (pancreatic metastasis): 3.3 mo |
Sheah et al[7], 2008 | Diagnostic pathway | 112 (100) | 9 (8.0) AM; 2 (1.8) RM | Myxoid liposarcoma | N/A | N/A |
- Citation: Smolle MA, Leithner A, Bernhardt GA. Abdominal metastases of primary extremity soft tissue sarcoma: A systematic review. World J Clin Oncol 2020; 11(2): 74-82
- URL: https://www.wjgnet.com/2218-4333/full/v11/i2/74.htm
- DOI: https://dx.doi.org/10.5306/wjco.v11.i2.74